

# Direct Enantioselective HPLC Monitoring of Lipase-Catalyzed Kinetic Resolution of Flurbiprofen

ASHRAF GHANEM\*

*Australian Centre for Research On Separation Science (ACROSS), School of Chemistry, University of Tasmania, Hobart, Tasmania, Australia*

**ABSTRACT** The solvent versatility of Chiralpak IB, a 3,5-dimethylphenylcarbamate derivative of cellulose-based chiral stationary phase, is demonstrated in the direct enantioselective HPLC monitoring of lipase-catalyzed kinetic resolution of flurbiprofen in nonstandard HPLC organic solvents. Nonstandard HPLC organic solvents were used as the reaction media for the lipase-catalysis and in mean time as diluent to dissolve the “difficult to dissolve” enzyme substrate (the acid) and as eluent for the simultaneous enantioselective HPLC baseline separation of both substrate and product in one run without any further derivatization. *Chirality* 22:597–603, 2010. © 2009 Wiley-Liss, Inc.

**KEY WORDS:** chiral separation; chiralpak IB; direct monitoring; enantioselective HPLC; flurbiprofen; HPLC; kinetic resolution; lipase

## INTRODUCTION

Flurbiprofen (*R*, *S*)-[2-(3-fluoro-4-phenyl) phenyl] propionic acid is one of the most prevalent nonsteroidal anti-inflammatory drugs (NSAIDs).<sup>1,2</sup> The *S*-enantiomer exhibits most of its anti-inflammatory activity, while the *R*-enantiomer enhances its gastrointestinal toxicity.<sup>3</sup> Furthermore, *R*-flurbiprofen blocks nociception in rats, indicating a different mechanism of analgesia and suggesting the use of this enantiomer, and possibly other *R*-aryl propionates, as analgesics.<sup>4</sup> Flurbiprofen is reported to be less prone to undergo chiral inversion *in vivo*.<sup>5,6</sup> Consequently, the resolution of flurbiprofen is particularly important.

To date, kinetic resolution is still one of the major strategies for resolution of racemic mixtures<sup>7</sup> using either chemical<sup>8</sup> or enzymatic<sup>9</sup> procedures. Indeed, enzymes are remarkable catalysts, capable of accepting a wide range of substrates, at the same time exhibiting highly chemo-, regio-, and enantioselectivity. Moreover, the price and availability of most classes of enzymes have significantly decreased over the last few years making them more economically attractive catalysts for the production of biologically active compounds.<sup>10</sup> Of particular interest, lipases were most commonly used as biocatalysts for the enzymatic resolution of racemates. Most lipases accept a broad range of non-natural substrates and are thus very versatile for applications in organic synthesis. They do not require cofactors and are commercially available in free and immobilized forms. In many cases, they exhibit good to excellent stereoselectivity.<sup>11</sup>

It is widely suggested that the lipase-catalyzed esterification be conducted in hydrophobic solvents.<sup>12,13</sup> However, the solubility of flurbiprofen is poor in the commonly used hydrophobic solvents, such as isooctane and *n*-hexane.<sup>14</sup> Thus, the reported lipase-catalyzed resolution of flurbiprofen has been performed in hydrophilic standard organic solvents, particularly, acetonitrile.<sup>14–16</sup> Nonstandard HPLC

organic solvents are seldom explored in the lipase-catalyzed kinetic resolution of racemates due to the difficulty associated with the enantioselective analysis. Nevertheless, if analyzed, they are not directly monitored as both substrate and product and not analyzed in one run.<sup>17,18</sup> The latter render the calculated enantiomeric excesses of both substrate and product inaccurate. This is due to the different response factor of the detector towards the substrate (acid) and product (esters) in case of lipase-catalyzed esterification or vice versa in case of enantioselective hydrolysis.

Lipase-catalyzed kinetic resolution of flurbiprofen in nonstandard HPLC solvents such as dichloromethane (DCM), ethyl acetate (EtOAc), methyl *tert*-butyl ether (*Mt*BE) and tetrahydrofuran (THF) might be the method of choice to overcome solubility problem of the substrate.<sup>19</sup> However, such nonstandard solvents might cause irreversible damage of the CSP by dissolving or swelling of the chiral selector.<sup>20–22</sup> Thus, reactions in nonstandard HPLC organic solvents are usually monitored off-line.<sup>20</sup>

Yet, a new generation of chiral packing materials for resolution of enantiomers by chromatography has been introduced by immobilizing the polysaccharide derivatives onto the chromatographic matrices.<sup>23–28</sup> Thus, series of immobilized polysaccharide-derived CSPs namely Chiralpak IA, Chiralpak IB and most recently Chiralpak IC became commercially available.<sup>29,30</sup> Such immobilization renders the polysaccharide derivatives insoluble in any


Dedicated to Professor Schurig on the occasion of his 70's birthday.

\*Correspondence to: Ashraf Ghanem, Pfizer Research Fellow/Lecturer Australian Centre for Research On Separation Science (ACROSS), School of Chemistry, University of Tasmania, Private Bag 75, Hobart, Tasmania 7001, Australia. E-mail: aghanem@utas.edu.au

Received for publication 28 May 2009; Accepted 11 August 2009

DOI: 10.1002/chir.20798

Published online 6 November 2009 in Wiley InterScience (www.interscience.wiley.com).



**Fig. 1.** Lipase-catalyzed enantioselective esterification of racemic flurbiprofen (**1**) using *n*-butanol in nonstandard HPLC organic solvents.

mobile phase solvent<sup>21,22</sup> and combines the benefits of the coated polysaccharide-type CSPs namely the broad application scope and the high preparative potential with enhanced robustness, practically unlimited solvent compatibility and extended range of applications.<sup>21–24</sup> Subsequently, broadening the choice of solvents able to be used as mobile phase eluent or diluents.<sup>19,20</sup>

Here, we report on the first direct enantioselective HPLC monitoring of lipase-catalyzed enantioselective access to enantiomerically pure/enriched flurbiprofen using nonstandard HPLC organic solvents as diluent to dissolve the enzyme substrate and eluent to analyze both substrate and product in one run without further derivatization.

## EXPERIMENTAL

### Instrumentation

The mobile phase for HPLC was filtered through a Millipore membrane filter (0.45 µl) from Nihon Millipore (Yonezawa, Japan) and degassed via Waters in-line degasser AF. The HPLC system consisted of a Waters binary pump, Model 1525, (Milford, MA), equipped with a dual k absorbance detector model 2487 and an autosampler model 717plus. The UV-detector was set at 300 nm. Chiralcel OD (4.6 mm × 250 mm ID coated on 5 ml silica-gel) and Chiralpak IB (4.6 mm × 250 mm ID immobilized on 5 ml silica-gel) column was purchased from Chiral Technologies Europe (Illkirch, France). The enantiomeric excess of the substrate (ees) and the product (eep) as well as the conversion (Conv.) and enantioselectivity (*E*) were calculated as previously described.<sup>31–33</sup>

### Materials

All solvents used as mobile phase in HPLC including 2-propanol were HPLC-grade and purchased from Fisher


Scientific (Fair Lawn, NJ). *n*-butanol used in the synthesis of ester was Analar grade and purchased from BDH chemicals (Poole, England). Lipases from *Aspergillus niger* (lipase AS), *Burkholderia cepacia* (formerly *Pseudomonas cepacia*) free (lipase PS) and immobilized on ceramic particles (lipase PS-C) together with *Candida rugosa* (lipase AYS) were gifts from Amano (Nagoya, Japan). Immobilized *Candida antarctica* lipase B (Novozym435), its free form (Novozym525), and immobilized *Rhizomucor miehei* lipase (lipozyme RM IM) were from Novo Nordisk (Bagsvaerd, Denmark). Lipase type VII from *Candida rugosa* (CRL) was from Sigma (Steinhiem, Germany). Lipase from *Candida cylindracea* (CCL), lipase immobilized in sol-gel-Ak on sintered glass from *Mucor miehei* (MML) and flurbiprofen were purchased from Fluka (Buchs, Switzerland).

### Chromatographic Conditions

The mobile phase was consisted of *n*-hexane/methyl *tert*-butyl ether/2-propanol/trifluoroacetic acid (85:15:0.4:0.1 v/v/v/v) and the flow rate was 1.3 ml/min. The column was operated at room temperature (24°C). UV detection was set at 254 nm.

### Chemical Synthesis of Racemic Butyl Ester of Flurbiprofen (**2**)

Few drops of conc. sulfuric acid were added to 0.04 M racemic flurbiprofen (**1**) in benzene followed by the addition of 360 µl of *n*-butanol (0.04 mol, 3 M equiv.). The mixture was stirred under reflux over night, solvent was evaporated under vacuum and the residue was neutralized with 10% sodium hydrogen carbonate. The ester was extracted twice using 30 ml diethyl ether. The ether was dried over sodium sulfate anhydrous, filtered, and evaporated under vacuum to afford 0.46 g pale yellowish oil (76% chemical yield).



**Fig. 2.** Baseline separation of racemic flurbiprofen (**1**) and its corresponding *n*-butyl ester **2** on Chiralpak IB. Chromatographic parameters including the separation factor ( $\alpha$ ) and the resolution (*R*<sub>s</sub>) are shown.

**TABLE 1. Enzymatic parameters including enantiomeric excesses of both substrate **1** and product **2**  $ee_s$  and  $ee_p$ , respectively, conversion and enantioselectivity ( $E$ ) of different lipases screened for the enantioselective esterification of flurbiprofen (**1**) using 1-butanol in acetonitrile**

Lipase	Time (h)	$ee_s$ (%)	$ee_p$ (%)	Conv. %	$E$
Novozym435	168	29.2	72.3	28.8	8.2
Novozym525	168	13.3	60.4	18.0	4.6
Lipozyme	168	4.7	17.6	21.0	1.4
Lipase AS	168	5.1	33.3	13.2	2.1
Lipase PS	168	3.4	33.3	9.2	2.0
Lipase AYS	168	4.7	9.5	33.0	1.2
CRL	168	6.0	9.0	39.7	1.2
Lipase PS-C	168	6.0	42.8	12.2	2.6
CCL	168	4.0	14.2	21.8	1.3
MML	168	4.0	33.3	10.7	2.0

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  6.8–7.7 (m, 8H, aromatic), 3.9 (t, 2H), 3.6 (q, 1H), 1.5 (m, 2H), 1.4 (d, 3H), 1.2 (m, 2H), 0.8 (t, 3H).

$^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$  130.7, 128.9, 128.4, 127.6, 126.9, 123.5, 115.4, 115.0, 64.8, 45.1, 30.6, 19.0, 18.3, 13.6, 12.2.

#### Lipase-Catalyzed Esterification of Flurbiprofen (**1**)

Ten milligrams (0.04 mmol) racemic flurbiprofen **1**, 10.8  $\mu\text{l}$  *n*-butanol (0.12 mmol, 3 equiv.), molecular sieves, and 2.0 ml either standard (acetonitrile) or nonstandard HPLC organic solvent (such as toluene, MtBE, EtOAc, THF or DCM) were added and stirred in a 4 ml reaction vial. The reaction mixture was thermostated at 40°C. Sample (50  $\mu\text{l}$ ) was withdrawn and injected at zero time (control).

Lipase (50 mg) was added and 50  $\mu\text{l}$  sample was withdrawn and directly injected to HPLC without dilution or workup at several time intervals.

#### Lipase-Catalyzed Hydrolysis of Flurbiprofen Butyl Ester (**2**)

Flurbiprofen butyl ester (12.2 mg; 0.04 mmol), 1.0 ml of solvent, and 1.0 ml of 0.1 M phosphate buffer (pH 7) were added to 4 ml reaction vial. The reaction mixture was thermostated at 40°C and 50  $\mu\text{l}$  sample of the nonstandard HPLC organic solvent aliquot was withdrawn and injected

at zero time (control). Lipase was (50 mg) added and 50  $\mu\text{l}$  samples of the nonstandard HPLC organic solvent aliquot were withdrawn at several time intervals. The samples were filtered and used directly without dilution for direct enantioselective HPLC analysis.


## RESULTS AND DISCUSSION

Organic solvents, as a reaction media, have an important role in determining the enantioselectivity in a lipase-catalyzed biotransformation reactions.<sup>34,35</sup> Moreover, versatility of the organic solvents in the mobile phase plays a crucial role in the achievement of the enantioselective HPLC baseline separation of the enzyme substrate and product in one run without further derivatization. These simultaneous baseline separations in one run is mandatory for the precise determination of the enantiomeric excesses of substrates and products. The latter is an important prerequisite for the detailed investigation of the enzyme-catalyzed enantioselective resolution of racemates.<sup>19,20</sup>

For the direct monitoring of the lipase-catalyzed enantioselective esterification of flurbiprofen **1** (cf. Fig. 1) in nonstandard solvents such as DCM, ethyl acetate (EtOAc), methyl *tert*-butyl ether (MtBE) and THF, the acid itself (**1**) and its corresponding ester (**2**) should be simultaneously baseline separated in their racemic synthesized form in one run without further derivatization using a chiral stationary phase that is compatible with these nonstandard organic solvents. Indeed, these solvents can not be used as mobile phase eluents in conventionally coated HPLC columns (e.g., Chiralcel OD).<sup>20–22</sup> Thus, the enantioselective HPLC separation of both synthesized racemic acid (**1**) and its corresponding butyl ester (**2**) was investigated using Chiralpak IB (the immobilized version of 3,5-dimethylphenylcarbamate derivative of cellulose-based chiral stationary phase, namely Chiralcel OD). Several investigations were performed using standard organic solvents consisting of *n*-hexane/2-propanol with different volume ratios. However, these combinations were not able to conduct the simultaneously baseline separation of both racemic acid (**1**) and its corresponding butyl ester (**2**) in one run. Thus, more investigations have been performed using the aforementioned nonstandard solvents solely or in combination with *n*-hexane in mobile phase composition using

**TABLE 2. Enzymatic parameters including enantiomeric excesses of substrate **1** and product **2**  $ee_s$  and  $ee_p$ , respectively, conversion and enantioselectivity ( $E$ ) of some selected lipases screened for the enantioselective esterification of flurbiprofen (**1**) using 1-butanol in several nonstandard organic solvents. Nr (no reaction)**

Lipase	Solvent	Log $P$	Time (h)	$ee_s$ (%)	$ee_p$ (%)	Conv. %	$E$
Novozym435	Toluene	2.50	6	87.7	67.6	56.4	14.5
	MtBE	1.30	96	84.8	71.8	54.1	16.1
	Ethyl acetate	0.68	120	14.5	63.8	18.5	5.2
	THF	0.49	Nr				
	DCM	1.30	72	15.6	91.3	14.6	25.8
Novozym525	Toluene	2.50	16	96.1	81.8	54.0	39.0
	MtBE	1.30	120	75.7	98.2	43.5	263.5
	Ethyl acetate	0.68	120	8.8	69.9	11.2	6.1
	THF	0.49	Nr				
	DCM	1.30	120	12.6	46.2	21.4	3.0



**Fig. 3.** HPLC chromatograms (from  $T = 0$  to  $T = 5$  d) showing the UV traces of both substrate **1** and product **2** during the direct HPLC monitoring of the reaction progress of Novozyme525-catalyzed enantioselective esterification of **1** using 1-butanol in MtBE as nonstandard HPLC solvent.

different ratios for the simultaneous separation of **1** and **2** in one run on Chiralpak IB. A simultaneous baseline separation of both racemic flurbiprofen (**1**) and its corresponding butyl ester (**2**) was achieved in one run using *n*-hexane associated with MtBE as a nonstandard HPLC organic solvent, 2-propanol and trifluoroacetic acid in mobile phase composition (*n*-Hex/MtBE/2-PrOH/trifluoroacetic acid (85:15:0.4:0.1 v/v/v/v) (Fig. 2).

*Chirality* DOI 10.1002/chir

Upon the fulfillment of the enantioselective baseline separation of the enzyme substrate (**1**) and the expected product (**2**), yet, the enzymatic reaction can be easily and directly HPLC monitored in either standard or nonstandard HPLC organic solvents. Thus, the screening of different lipases for the enantioselective esterification of flurbiprofen (Fig. 1) was first performed in acetonitrile ( $\log P = -0.34$ ) as standard organic solvent. Of all 10 tested




Fig. 4. Lipase-catalyzed enantioselective hydrolysis of butyl ester (**2**) in a biphasic system consisting of nonstandard solvent and phosphate buffer pH 7.

lipases, only lipase from *Candida antarctica* lipase B CAL-B (Novozym435 and Novozym525) showed better activity and enantioselectivity (also called enantiomeric ratio)  $E$ . The rest did not show any promising results even after 168 hrs. Results are shown in Table 1. Due to the R-stereopreference of *Candida antarctica* lipase B,<sup>15,18</sup> the enantioselective esterification of racemic **1** [(*RS*)-**1**], (*R*)-**1** was the faster reacting enantiomer which was selectively esterified to afford its corresponding butyl ester (*R*)-**2** leaving the second enantiomer of the substrate (*S*)-**1** in enantiomerically enriched form. This was achieved when using different lipases in presence of *n*-butanol in acetonitrile as standard organic solvent (cf. Table 1).

Based on the aforementioned results, two lipases were selected for further investigation in nonstandard organic solvents. Thus, lipase from *Candida Antarctica* CAL-B (Novozym435) and its free form (Novozym525) were used for the enantioselective esterification of racemic flurbiprofen **1** in nonstandard HPLC solvents such as toluene, methyl *tert*-butyl ether (MtBE), ethyl acetate (EtOAc), THF and DCM, results are summarized in Table 2. The reactions were directly monitored by enantioselective HPLC using Chiralpak IB without further workup or removal of the nonstandard solvent. In comparison with the lipase-catalyzed kinetic resolution of (**1**) in acetonitrile as standard organic solvent, excellent enantioselectivities  $E$ , enantiomeric excesses of both substrate (**1**) and product (**2**) and faster reaction rates were observed when using nonstandard HPLC organic solvents.

TABLE 3. Enzymatic parameters including enantiomeric excesses of both substrate **2** and product **1**  $ee_s$  and  $ee_p$ , respectively, conversion and enantioselectivity ( $E$ ) of different lipases screened for the enantioselective hydrolysis of racemic flurbiprofen butyl ester (**2**) in a biphasic system consisting of MtBE as organic solvent and phosphate buffer pH 7

Lipase	Time (h)	$ee_s$ (%)	$ee_p$ (%)	Conv. %	$E$
Novozym435	72	24.9	22.5	52.4	1.9
Novozym525	96	25.6	19.9	56.3	1.8
Lipozyme	168	9.0	14.2	0.3	1.4
Lipase AS	168	12.8	50.0	0.2	3.4
Lipase PS	168	12.3	77.7	0.1	9.0
Lipase AYS	168	13.1	41.1	0.2	2.7
CRL	168	11.1	93.7	0.1	34.8
Lipase PS-C	168	11.7	62.5	0.1	4.8
CCL	168	11.7	13.2	0.4	1.4
MML	168	9.3	17.0	0.3	1.5

In terms of enantioselectivity ( $E$ ), enantiomeric excess of the resulting product ( $ee_p$ ) (*R*-ester) at maximum conversion (43.5%), lipase from *Candida antarctica* B (CAL-B) known as Novozym525 showed the best performance in MtBE having  $\log P$  1.30 ( $ee_s = 75.7\%$ ,  $ee_p = 98.2\%$ ,  $E = 263.5$  after 120 hrs) (cf. Fig. 3). While in toluene ( $\log P$  2.50) Novozym525 showed very good enantioselectivity and enantiomeric excess of unreacted substrate ( $ee_s$ ) (*S*-acid) at maximum conversion (54.0%), in shorter time ( $ee_s = 96.1\%$ ,  $ee_p = 81.8\%$ ,  $E = 39.0$  after 16 hrs).  $\log P$  in Table 2 is defined as the ratio of concentration of a substance in two immiscible phases at equilibrium namely octanol




Fig. 5. Selected HPLC chromatograms (from  $t = 0$  to  $t = 3$  d) showing UV traces of both substrate **2** and product **1** during the direct HPLC monitoring of the reaction progress of Novozym435-catalyzed enantioselective hydrolysis of flurbiprofen butyl ester (**2**) in a biphasic system consisting of MtBE and phosphate buffer pH 7.

**TABLE 4. Enzymatic parameters including enantiomeric excesses of both substrate **2** and product **1**  $ee_s$  and  $ee_p$ , respectively, conversion and enantioselectivity ( $E$ ) of selected lipases screened for the enantioselective hydrolysis of racemic flurbiprofen butyl ester (**2**) in a biphasic system consisting of different organic solvents and phosphate buffer pH 7**

Lipase	Solvent	Time (h)	$ee_s$ (%)	$ee_p$ (%)	Conv. %	$E$
Novozym435	Toluene	144	17.8	4.7	12.6	1.2
	Ethyl acetate	144	8.9	89.9	9.0	20.6
	DCM	144	9.0	33.5	6.4	2.1
Novozym525	Toluene	144	6.6	39.1	2.3	2.4
	Ethyl acetate	144	8.1	88.8	8.4	18.4
	DCM	144	8.2	13.3	0.6	1.4

and water and used to describe the correlation of hydrophobicity and the enantioselectivity  $E$  of lipases.<sup>19</sup>

Compared to the esterification experiments in the nonaqueous medium consisting of standard and nonstandard HPLC organic solvents described above, the enzymatic hydrolysis of the butyl ester (*RS*)-**2** in aqueous medium proceeded slowly (cf. Fig. 4). Only two lipases namely Novozym435 and 525 were able to conduct poor enantioselective resolution when MtBE was used in combination with sodium phosphate buffer pH 7 in a biphasic system ( $ee_s$  24.9 %,  $ee_p$  22.5, Conv. 52.4 %,  $E = 1.9$ ) for Novozym435 and ( $ee_s$  25.6 %,  $ee_p$  19.9, Conv. 56.3 %,  $E = 1.8$  for Novozym525) Table 3. These results promote us to study the screening of both enzymes for the enantioselective hydrolysis of racemic (**2**) in other nonstandard HPLC organic solvents namely toluene, EtOAc and DCM. Results are summarized in Table 4. In terms of the enantioselectivity ( $E$ ), enantiomeric excesses of unreacted substrate ( $ee_s$  of the ester (*S*)-**2**), enantiomeric excess of the resulting product ( $ee_p$  of the acid (*R*)-**1**) and the reaction time at maximum conversion (52.4%), lipase from *Candida antarctica* B (CAL-B) known as Novozym435 showed the best performance when used in a biphasic solvents consisting of MtBE and buffer pH 7 ( $ee_s$  24.9 %,  $ee_p$  22.5, Conv. 52.4 %,  $E = 1.9$  after 72 hours) (cf. Fig. 5).

## CONCLUSION

Nonstandard organic solvent is a mandatory mobile phase component to achieve the enantioselective baseline separation of flurbiprofen and its corresponding *n*-butyl ester in on run. Such baseline enantioselective HPLC separation would not be achieved without the immobilization of chiral selector as in Chiralpak IB. Moreover, the lipase-catalyzed esterification in nonstandard solvents showed very high activity and enantioselectivity  $E$  (263 within 120 hrs and 39 within 16 hrs for MtBE and toluene, respectively). These biotransformation reactions were easily monitored by direct enantioselective HPLC equipped with immobilized chiral stationary phase, namely, Chiralpak IB and a UV-detector. This direct enantioselective HPLC monitoring in nonstandard organic solvents could offer unique

capabilities to allow the exploration of the enantioselectivity of lipases toward "difficult to dissolve" substrates in harsh organic solvents.

## ACKNOWLEDGMENTS

The author thanks Prof. Nabil Aboul-Enein, Prof. Aida Al-Azouny, and Mr. M. Farrag, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre (NRC), Dokki-Cairo, Egypt for their scientific supports and discussions.

## LITERATURE CITED

- Hayball PJ. Chirality and nonsteroidal anti-inflammatory drugs. *Drugs* 1996;52:47–58.
- Alcantara AR, Sanchez-Montero JM, Sinisterra JV, Patel RN, editors. *Stereoselective biocatalysis*, Vol. 22. New York: Marcel Dekker; 2000. p 659.
- Bhandarkar SV, Neau SH. Lipase-catalyzed enantioselective esterification of flurbiprofen with *n*-butanol. *Electron J Biotechnol* 2000;3:195–201.
- Brune K, Beck WS, Geisslinger G, Menzel-Soglowek S, Peskar BM, Peskar BA. Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. *Experientia* 1991;47:257–261.
- Geisslinger G, Ferreira SH, Menzel S, Schlott D, Brune K. Antinociceptive actions of *R*(2)-flurbiprofen non-cyclooxygenase inhibiting 2-arylpropionic acid in rats. *Life Sci* 1994;54:173–177.
- Wechter WJ. Drug chirality: on the mechanism of *R*-aryl propionic acid class NSAIDs. Epimerization in humans and the clinical implications for the use of racemates. *J Clin Pharmacol* 1994;34:1036–1042.
- Dehli JR, Gotor V. Parallel kinetic resolution of racemic mixtures: a new strategy for the preparation of enantiopure compounds. *Chem Soc Rev* 2002;31:365–370.
- Kagan HB, Fiaud JC. Kinetic resolution. *Top Stereochem* 1988;18: 249–330.
- Sih CJ, Wu SH. Resolution of enantiomers via biocatalysis. *Top Stereochem* 1989;19:63–125.
- Ghanem A. Trends in lipase-catalyzed asymmetric access to enantiomerically pure/enriched compounds. *Tetrahedron* 2007;63:1721–1754.
- Ghanem A, Aboul-Enein HY. Applications of lipases in kinetic resolution of racemates. *Chirality* 2005;17:1–15.
- Klibanov AM. Enzymatic catalysis in anhydrous organic solvents. *Trends Biochem Sci* 1989;14:141–144.
- Dordick JS. Enzymatic catalysis in monophasic organic solvents. *Enzyme Microb Technol* 1989;11:194–211.
- Duan G, Ching CB. Preparative scale enantioseparation of flurbiprofen by lipase-catalysed reaction. *Biochem Eng J* 1998;2:237–245.
- Arroyo M, Sinisterra JV. High enantioselective esterification of 2-arylpropionic acids catalyzed by immobilized lipase from *Candida antarctica*: a mechanistic approach. *J Org Chem* 1994;59:4410–4417.
- Morrone R, Nicolosi G, Patti A, Piattelli M. Resolution of racemic flurbiprofen by lipase-mediated esterification in organic solvent. *Tetrahedron Asymmetry* 1995;6:1773–1778.
- Spizzo P, Basso A, Ebert C, Gardossi L, Ferrario V, Romano D, Molinari F. Resolution of (*R,S*)-flurbiprofen catalysed by dry mycelia in organic solvent. *Tetrahedron* 2007;63:11005–11010.
- Jhang HY, Wang X, Ching CB. *R*-stereopreference analysis of lipase Novozym435 in kinetic resolution of flurbiprofen. *Chirality* 2007;19: 245–249.
- Ghanem A, Aboul-Enein MN, El-Azzouny A, El-Beairy MF, Al-Humaidi E, Al-Ahdal MN, Alaidan AA, Amin K. Direct enantioselective HPLC monitoring of lipase-catalyzed kinetic resolution of tiaprofenic acid in non-standard organic solvents. *Chirality* 2008;20:871–877.

20. Ghanem A, El-Beairy MF, Al-Ahdal MN. Direct enantioselective HPLC monitoring of lipase-catalyzed kinetic resolution of racemates in non-standard organic solvents. *Chromatographia* 2007; 65:681–686.
21. Zhang T, Nguyen D, Franco P, Murakami T, Ohnishi A, Kurosawa H. Cellulose 3,5-dimethylphenylcarbamate immobilized on silica: a new chiral stationary phase for the analysis of enantiomers. *Anal Chim Acta* 2006;557:221–228.
22. Zhang T, Kientzy C, Franco P, Ohnishi A, Kagamihara Y, Kurosawa H. Solvent versatility of immobilized 3,5-dimethylphenylcarbamate of amylose in enantiomeric separations by HPLC. *J Chromatogr A* 2005;1075:65–75.
23. Ghanem A, Naim L. Immobilized versus coated amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phases for the enantioselective separation of cyclopropane derivatives by liquid chromatography. *J Chromatogr A* 2006;1101:171–178.
24. Ghanem A. True and false reversal of the elution order of barbiturates on a bonded cellulose-based chiral stationary phase. *J Chromatogr A* 2006;1132:329–332.
25. Kamal A, Sanbhor M, Shaik AA, Sravanthi V. One-pot synthesis and resolution of chiral allylic alcohols. *Tetrahedron Asymmetry* 2003;14: 2839–2844.
26. Francotte ER. Enantioselective chromatography as a powerful alternative for the preparation of drug enantiomers. *J Chromatogr A* 2001; 906:379–397.
27. Yashima E, Fukaya H, Okamoto YJ. 3,5-dimethylphenylcarbamates of cellulose and amylose regioselectively bonded to silica gel as chiral stationary phases for high-performance liquid chromatography. *J Chromatogr A* 1994;677:11–19.
28. Okamoto Y, Enomoto N, Furukawa S, Ogasawara Y, Akano H, Kawamura Y. Eur. Pat. 0625524 B1. Nakano Vinegar Co. Ltd, Japan, 23-11-1994.
29. Chankvetadze B, Ikai T, Yamamoto C, Okamoto Y. High-performance liquid chromatographic enantioseparations on monolithic silica columns containing a covalently attached 3,5-dimethylphenylcarbamate derivative of cellulose. *J Chromatogr A* 2004;1042:55–60.
30. Chen X, Liu Y, Qin F, Kong L, Zou H. Synthesis of covalently bonded cellulose derivative chiral stationary phases with a bifunctional reagent of 3-(triethoxysilyl)propyl isocyanate. *J Chromatogr A* 2003;1010: 185–194.
31. Ghanem A, Aboul-Enein MN, El-Azzouny A, El-Beairy MF. On the solvents versatility of immobilized amylose and cellulose-based chiral stationary phases in enantioselective LC separation and monitoring of bio-catalyzed resolutions of acidic drugs in non-standard organic solvents. *Chromatographia* 2009;70:349–363.
32. Ghanem A, Schurig V. Lipase-catalysed transesterification of 1-(2-furyl) ethanol using isopropenylacetate. *Chirality* 2001;13:118–123.
33. Chen CS, Fujimamoto Y, Girdaukas G, Sih CJ. Quantitative analyses of biochemical kinetic resolutions of enantiomers. *J Am Chem Soc* 1982;104:7294–7299.
34. Wescot CR, Klibanov KM. Solvent variation inverts substrate specificity of an enzyme. *J Am Chem Soc* 1993;115:1629–1631.
35. Nakamura K, Kinoshita M, Ohno A. Effect of solvent on lipase-catalyzed transesterification in organic media. *Tetrahedron* 1994;50:4681–4690.